At a glance
ClinicalIndex Comparison RecordN/ACompleted· 68 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prognostic Value of the Levels of Circulating Tumor Cells (CTCs) in Peripheral Blood in Patients With Prostate Cancer at High Risk (Clinical Stages IIB-III) Treated Radically With Radiotherapy and Hormone Therapy.
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa·observational·Posted Feb 27, 2013·Updated Jun 26, 2020
In Brief
An observational study for Patients With High-risk Prostate Cancer. Completed, enrolled 68 participants across 3 sites.
Detailed Summary
The detection and quantification of Circulating tumor cells CTCs in peripheral blood of patients with prostate adenocarcinoma may be useful at least for: Getting a correct stratification of patients with high-risk prostate cancer (PCa). Set the prognosis at baseline. Evaluate the response to different treatments (predictive value and monitoring). Establish individualized therapies.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPatients With High-risk Prostate Cancer
CountriesSpain
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartJan 2014
Primary CompletionDec 2018
TodayJul 2026
First PostedFeb 27, 2013
Enrollment StartJan 1, 2014
Primary CompletionDec 21, 2018
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 13.3 years ago